Merck (MRK) announced a bold cost-cutting strategy aiming to save $3 billion annually by 2027, reflecting a major operational ...

Merck Q2 earnings beat estimates but revenue fell short. Gardasil sales dropped while Keytruda and other treatments drove ...

Merck’s CEO recently shared insights on minimal impacts from EU tariffs and highlighted challenges in Gardasil production.

Merck is undergoing a strategic restructuring, resulting in immediate job cuts in administration, sales, and research as part of a plan to save $3 billion by 2027.

Merck stock fell early Tuesday after Q2 results. The Dow Jones drugmaker plans for job cuts as part of restructuring ...

Merck & Co. Inc. (NYSE:MRK) shares fell over 6% in early trading Tuesday after the pharmaceutical giant reported a mixed ...

Along with its financial results for the second quarter of 2025, Merck revealed a restructuring plan to save $3 billion by ...

Robert F. Kennedy Jr. announces plans to reform the Vaccine Injury Compensation Program, addressing claims of inefficiency ...

Merck is a strong and profitable pick meeting Benjamin Graham's criteria. Read more on why investors need to stay aware of ...

As Keytruda generic competition looms larger on the horizon, the company is hoping to reinvest the savings into pipeline ...

As Merck & Co. rolls out a widespread cost-cutting initiative, the pharma is dropping an autoimmune asset acquired a few years ago in a nearly $2 billion biotech takeover.